Life science technology company PacBio (NASDAQ:PACB), a developer of advanced sequencing solutions, and microbiome research and discovery specialist Intus Bio announced on Friday the launch of GutID, the first commercial human gut health test powered by PacBio's HiFi sequencing technology and Intus Bio's Titan-1 platform.

GutID is designed to provide a comprehensive and accurate analysis of the gut microbiome, including strain-level identification of both beneficial and pathogenic bacteria.

The test utilises PacBio's long-read sequencing technology, enabling high-resolution analysis of the microbiome and delivering robust and repeatable results.

GutID is targeted at individuals seeking to understand and improve their gut health, and is particularly beneficial for those with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

The test involves a simple at-home sample collection and provides users with a detailed report, including a microbiome health score and personalised recommendations.